11.12.2023 07:14:50
|
Press Release: Basilea announces that FDA -2-
This communication expressly or implicitly contains certain forward-looking statements, such as "believe", "assume", "expect", "forecast", "project", "may", "could", "might", "will" or similar expressions concerning Basilea Pharmaceutica Ltd, Allschwil and its business, including with respect to the progress, timing and completion of research, development and clinical studies for product candidates. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of Basilea Pharmaceutica Ltd, Allschwil to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Basilea Pharmaceutica Ltd, Allschwil is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.
For further information, please contact:
Peer Nils Schröder, PhD
Head of Corporate Communications & Investor Relations
Basilea Pharmaceutica Ltd, Allschwil
Hegenheimermattweg 167b
4123 Allschwil
Switzerland
Phone +41 61 606 1102
E-mail media_relations@basilea.com
investor_relations@basilea.com
This press release can be downloaded from www.basilea.com.
References
1. ClinicalTrials.gov identifier: NCT03816176A. C. Arrieta, H. Segers, J. D.
Deville et al. Safety and Outcomes of Isavuconazonium Sulfate for the
Treatment of Invasive Aspergillosis or Invasive Mucormycosis in Pediatric
Patients. IDWeek 2023, Abstract #1124
2. ClinicalTrials.gov identifier: NCT03241550A. C. Arrieta, M. Neely, J. C.
Day, et al. Tolerability, and Population Pharmacokinetics of Intravenous
and Oral Isavuconazonium Sulfate in Pediatric Patients. Antimicrobial
Agents and Chemotherapy 2021;65(8):e0029021
3. IQVIA Analytics Link, June 2023. In-market sales reported as moving
annual total (MAT) in US dollar.
4. European Public Assessment Report (EPAR) Cresemba:
https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba
https://www.ema.europa.eu/en/medicines/human/EPAR/cresemba [Accessed:
December 10, 2023]
5. The registration status and approved indications may vary from country to
country.
6. J. Cadena, G. R. Thompson 3rd, T. F..Patterson. Aspergillosis:
Epidemiology, Diagnosis, and Treatment. Infectious Disease Clinics of
North America 2021 (35), 415-434
7. M. Slavin, S. van Hal, T. C. Sorrell et al. Invasive infections due to
filamentous fungi other than Aspergillus: epidemiology and determinants
of mortality. Clinical Microbiology and Infection 2015 (21),
490.e1-490.e10
8. Z. D. Pana E. Roilides, A. Warris et al. Epidemiology of Invasive Fungal
Disease in Children. Journal of the Pediatric Infectious Diseases Society
2017 (6), suppl. 1, S3-S11
Attachment
-- Press release (PDF)
https://ml-eu.globenewswire.com/Resource/Download/09ae6cff-f7a4-4291-8757-65734f5257ab
(END) Dow Jones Newswires
December 11, 2023 01:15 ET (06:15 GMT)
Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!